Cargando…

Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis

We conducted a meta-analysis to systematically evaluate the efficacy and safety of treatment with or without pertuzumab for human epidermal growth factor receptor-2 -positive (HER2)-positive breast cancer and provided evidence-based reference for clinical use. METHODS: The Cochrane Library, PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xuan, Li, Yuqing, Lin, Mingfei, Lu, Yufu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237690/ https://www.ncbi.nlm.nih.gov/pubmed/37266600 http://dx.doi.org/10.1097/MD.0000000000033925

Ejemplares similares

Safety and efficacy evaluation of pertuzumab in patients with solid tumors
por: Zhu, Chenjing, et al.
Publicado: (2017)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
por: Chen, Shanshan, et al.
Publicado: (2019)

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies
por: Luo, Qian, et al.
Publicado: (2019)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy
por: Ishii, Kei, et al.
Publicado: (2019)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
por: Maly, Joseph J, et al.
Publicado: (2014)

Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
por: Liu, Yan-cui, et al.
Publicado: (2019)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
por: Sun, Maoben, et al.
Publicado: (2023)

6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers
por: Lee, Seokwon, et al.
Publicado: (2021)

Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies
por: Liu, Lin, et al.
Publicado: (2016)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
por: Li, Dailong, et al.
Publicado: (2022)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Efficacy and safety of elemene combined with chemotherapy in advanced gastric cancer: A Meta-analysis
por: Liu, Ying, et al.
Publicado: (2020)

Prone position versus supine position in postoperative radiotherapy for breast cancer: A meta-analysis
por: Lai, Junming, et al.
Publicado: (2021)

The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis
por: Huang, Yang, et al.
Publicado: (2021)

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status
por: Wang, Yan, et al.
Publicado: (2021)

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
por: Takahashi, Kenta, et al.
Publicado: (2020)

Efficacy and safety of acupuncture for chemotherapy-induced leukopenia: A systematic review and meta-analysis
por: Nian, Jiayun, et al.
Publicado: (2022)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
por: Chen, Qi-Feng, et al.
Publicado: (2019)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report
por: Meng, Xiangying, et al.
Publicado: (2017)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

The efficacy and safety of neoadjuvant nimotuzumab for gastric cancer: A meta-analysis of randomized controlled studies
por: Cao, Bin, et al.
Publicado: (2021)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Ouyang, Guoqing, et al.
Publicado: (2021)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_urjdab8l7bvps2gqg9s15vf8od